- Home
- SQ vs TAK Comparison
SQ vs TAK Comparison
Compare SQ & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQ
- TAK
- Stock Information
- Founded
- SQ 2009
- TAK 1781
- Country
- SQ United States
- TAK Japan
- Employees
- SQ N/A
- TAK N/A
- Industry
- SQ Computer Software: Prepackaged Software
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- SQ Technology
- TAK Health Care
- Exchange
- SQ Nasdaq
- TAK Nasdaq
- Market Cap
- SQ 44.7B
- TAK 43.9B
- IPO Year
- SQ 2015
- TAK N/A
- Fundamental
- Price
- SQ $84.32
- TAK $13.63
- Analyst Decision
- SQ Buy
- TAK
- Analyst Count
- SQ 31
- TAK 0
- Target Price
- SQ $91.24
- TAK N/A
- AVG Volume (30 Days)
- SQ 8.6M
- TAK 1.3M
- Earning Date
- SQ 11-07-2024
- TAK 10-31-2024
- Dividend Yield
- SQ N/A
- TAK 4.65%
- EPS Growth
- SQ N/A
- TAK 49.73
- EPS
- SQ 1.66
- TAK 1.27
- Revenue
- SQ $23,861,534,000.00
- TAK $31,732,209,416.00
- Revenue This Year
- SQ $15.88
- TAK $4.41
- Revenue Next Year
- SQ $10.94
- TAK $1.09
- P/E Ratio
- SQ $50.71
- TAK $21.56
- Revenue Growth
- SQ 14.75
- TAK 9.43
- 52 Week Low
- SQ $55.00
- TAK $12.58
- 52 Week High
- SQ $90.00
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- SQ 67.41
- TAK 39.22
- Support Level
- SQ $69.03
- TAK $13.46
- Resistance Level
- SQ $90.00
- TAK $13.75
- Average True Range (ATR)
- SQ 3.30
- TAK 0.16
- MACD
- SQ 0.98
- TAK -0.01
- Stochastic Oscillator
- SQ 72.91
- TAK 21.15
About SQ Block Inc.
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.